June 12, 2017

(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) issued the following statement regarding today’s ruling by the United States Supreme Court in Sandoz v. Amgen:

“The Supreme Court’s ruling on biosimilars will help create more competition among costly biologic medications, which is the key to reducing overall prescription drug costs for consumers, employers, government programs, and others.”